Expert analysis of CRISPR therapeutics, gene editing clinical trials, base editing platforms, pharmaceutical licensing deals, FDA regulatory pathways, and the commercial landscape of gene medicine.
The world's first gene editing drug approval and what it means for every pharma company still on the sidelines.
Fourth-generation CRISPR tools and the extraordinary expansion of correctable genetic diseases they enable.
The case for owning the domain at the most commercially productive intersection in modern medicine.
Delivering CRISPR directly into patients — liver, heart, muscle, brain — and the pharmaceutical infrastructure required to make it work safely at scale.
The Broad Institute vs Berkeley dispute, current licensing structures, and what the IP landscape means for CRISPR pharmaceutical development.
The deals, partnerships, and acquisitions bringing pharmaceutical giants into the CRISPR era.